biostudies-literatureUnknown16Xu Y<h4>Introduction</h4>This study assessed the safety and efficacy of B cell- and anti-PLA2R antibody-targeted low-dose rituximab therapy in patients with idiopathic membranous nephropathy (IMN).<h4>Methods</h4>This was a multicenter, investigator-initiated, open-label, prospective cohort study. Patients were recruited from 10 hospitals in the east coastal region of China between November 1^st, 2019 and June 15^th, 2023. Enrolled patients were assigned to individualized rituximab therapy (guided by peripheral B cells and anti-PLA2R antibody levels) or standard rituximab therapy (1,000 mg × 2 or 375 mg/m² × 3-4): the individualized group (n = 78) and the standard group (n = 62). Odds ratios (ORs) and 95% confidence intervals (CIs) for response were estimated using multivarFrontiers in immunology1633532https://www.ebi.ac.uk/biostudies/studies/S-EPMC12484018biostudies-literatureB cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China.PMC12484018Shen LLiu JSun BXing CMao HZhang LWang LLiu XWan CBi GWang NBian SSun DZhou GZhang CZhang BZhou HYuan YYang MChen LZeng MLu FLu GZhang XJiang CLiu CXu YfalseB cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China.<h4>Introduction</h4>This study assessed the safety and efficacy of B cell- and anti-PLA2R antibody-targeted low-dose rituximab therapy in patients with idiopathic membranous nephropathy (IMN).<h4>Methods</h4>This was a multicenter, investigator-initiated, open-label, prospective cohort study. Patients were recruited from 10 hospitals in the east coastal region of China between November 1^st, 2019 and June 15^th, 2023. Enrolled patients were assigned to individualized rituximab therapy (guided by peripheral B cells and anti-PLA2R antibody levels) or standard rituximab therapy (1,000 mg × 2 or 375 mg/m² × 3-4): the individualized group (n = 78) and the standard group (n = 62). Odds ratios (ORs) and 95% confidence intervals (CIs) for response were estimated using multivar2025-01-01T00:00:00Z20252026-06-04T02:30:21.194Z2026-05-04T03:13:46.564ZS-EPMC124840184104132510.3389/fimmu.2025.1633532